200 related articles for article (PubMed ID: 21631272)
1. p63 expression in giant cell-containing lesions of bone and soft tissue.
de la Roza G
Arch Pathol Lab Med; 2011 Jun; 135(6):776-9. PubMed ID: 21631272
[TBL] [Abstract][Full Text] [Related]
2. P63 expression as a biomarker discriminating giant cell tumor of bone from other giant cell-rich bone lesions.
Shooshtarizadeh T; Rahimi M; Movahedinia S
Pathol Res Pract; 2016 Oct; 212(10):876-879. PubMed ID: 27473669
[TBL] [Abstract][Full Text] [Related]
3. Giant cell tumor of bone express p63.
Dickson BC; Li SQ; Wunder JS; Ferguson PC; Eslami B; Werier JA; Turcotte RE; Kandel RA
Mod Pathol; 2008 Apr; 21(4):369-75. PubMed ID: 18311114
[TBL] [Abstract][Full Text] [Related]
4. Can p63 serve as a biomarker for giant cell tumor of bone? A Moroccan experience.
Hammas N; Laila C; Youssef AL; Hind el F; Harmouch T; Siham T; Afaf A
Diagn Pathol; 2012 Sep; 7():130. PubMed ID: 23016917
[TBL] [Abstract][Full Text] [Related]
5. Immunohistochemical analysis of 36 cases of chondroblastomas: A single institutional experience.
Rekhi B; Ghate S; Shah A; Ramadwar M; Gulia A
Ann Diagn Pathol; 2020 Feb; 44():151440. PubMed ID: 31862519
[TBL] [Abstract][Full Text] [Related]
6. Gene expression profiling identifies p63 as a diagnostic marker for giant cell tumor of the bone.
Lee CH; Espinosa I; Jensen KC; Subramanian S; Zhu SX; Varma S; Montgomery KD; Nielsen TO; van de Rijn M; West RB
Mod Pathol; 2008 May; 21(5):531-9. PubMed ID: 18192965
[TBL] [Abstract][Full Text] [Related]
7. Soft-tissue and bone tumors about the foot and ankle.
Walling AK; Gasser SI
Clin Sports Med; 1994 Oct; 13(4):909-38. PubMed ID: 7805113
[TBL] [Abstract][Full Text] [Related]
8. Utility of P63 in Differentiating Giant Cell Tumor from Other Giant Cell-Containing Lesions.
Hui M; Uppin SG; Kumar KK; Radhika S; Chandrasekhar P; Rao KN
Turk Patoloji Derg; 2022; 38(1):9-15. PubMed ID: 34514571
[TBL] [Abstract][Full Text] [Related]
9. A diagnosis of giant cell-rich tumour of bone is supported by p63 immunohistochemistry, when more than 50 % of cells is stained.
Maues De Paula A; Vasiljevic A; Giorgi R; Gomez-Brouchet A; Aubert S; Leroy X; Duval H; de Pinieux G; Bouvier C
Virchows Arch; 2014 Oct; 465(4):487-94. PubMed ID: 25100342
[TBL] [Abstract][Full Text] [Related]
10. Immunohistochemical evaluation of microphthalmia-associated transcription factor expression in giant cell lesions.
Seethala RR; Goldblum JR; Hicks DG; Lehman M; Khurana JS; Pasha TL; Zhang PJ
Mod Pathol; 2004 Dec; 17(12):1491-6. PubMed ID: 15205688
[TBL] [Abstract][Full Text] [Related]
11. L-type amino acid transporter-1 and CD98 expression in bone and soft tissue tumors.
Koshi H; Sano T; Handa T; Yanagawa T; Saitou K; Nagamori S; Kanai Y; Takagishi K; Oyama T
Pathol Int; 2015 Sep; 65(9):460-7. PubMed ID: 26134029
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemistry for histone H3G34W and H3K36M is highly specific for giant cell tumor of bone and chondroblastoma, respectively, in FNA and core needle biopsy.
Schaefer IM; Fletcher JA; Nielsen GP; Shih AR; Ferrone ML; Hornick JL; Qian X
Cancer Cytopathol; 2018 Aug; 126(8):552-566. PubMed ID: 29757500
[TBL] [Abstract][Full Text] [Related]
13. RANK signalling in bone lesions with osteoclast-like giant cells.
Won KY; Kalil RK; Kim YW; Park YK
Pathology; 2011 Jun; 43(4):318-21. PubMed ID: 21532526
[TBL] [Abstract][Full Text] [Related]
14. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours.
Conner JR; Hornick JL
Histopathology; 2013 Jul; 63(1):36-49. PubMed ID: 23701429
[TBL] [Abstract][Full Text] [Related]
15. Expression of regulatory apoptotic proteins in peripheral giant cell granulomas and lesions containing osteoclast-like giant cells.
Pammer J; Weninger W; Hulla H; Mazal P; Horvat R
J Oral Pathol Med; 1998 Jul; 27(6):267-71. PubMed ID: 9707279
[TBL] [Abstract][Full Text] [Related]
16. [Expression of H3.3 G34W mutant-specific antibody in giant cell tumors of bone and its diagnostic value].
Wang X; Wu N; Zhang RS; Wei X; Ji RH; Ma HH; Zhou XJ; Rao Q
Zhonghua Bing Li Xue Za Zhi; 2020 Feb; 49(2):116-121. PubMed ID: 32074722
[No Abstract] [Full Text] [Related]
17. Is Core Needle Biopsy Reliable in Differentiating Between Aggressive Benign and Malignant Radiolucent Bone Tumors?
Hegde V; Burke ZDC; Park HY; Zoller SD; Johansen D; Kelley BV; Levine B; Motamedi K; Federman NC; Seeger LL; Nelson SD; Bernthal NM
Clin Orthop Relat Res; 2018 Mar; 476(3):568-577. PubMed ID: 29529643
[TBL] [Abstract][Full Text] [Related]
18. Mutation Analysis of H3F3A and H3F3B as a Diagnostic Tool for Giant Cell Tumor of Bone and Chondroblastoma.
Cleven AH; Höcker S; Briaire-de Bruijn I; Szuhai K; Cleton-Jansen AM; Bovée JV
Am J Surg Pathol; 2015 Nov; 39(11):1576-83. PubMed ID: 26457357
[TBL] [Abstract][Full Text] [Related]
19. p63 immunohistochemical staining is limited in soft tissue tumors.
Jo VY; Fletcher CD
Am J Clin Pathol; 2011 Nov; 136(5):762-6. PubMed ID: 22031315
[TBL] [Abstract][Full Text] [Related]
20. [Benign and malignant giant-cell rich lesions of bone: Pathological diagnosis with special emphasis on recent immunohistochemistry and molecular techniques].
Macagno N; Caselles K; Aubert S; Audard V; Gomez-Brouchet A; Galant C; Guinebretière JM; Karanian M; Larousserie F; Marie B; de Pinieux G; Bouvier C
Ann Pathol; 2018 Apr; 38(2):92-102. PubMed ID: 29580573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
